News from ECTRIMS 2025 (1)
Those who have been with DocBlog for a while know: autumn is congress time. As always at this time, the world’s largest MS meeting took place again this year – almost 10,000 MS experts from
Continue reading
Tag: “Ocrelizumab”
MS Topics at Neurologist Congress AAN 2025
The annual meeting of the American Academy of Neurology (AAN) is the largest neurological congress worldwide and covers all sub-areas of neurology. The AAN is not necessarily the most important meeting for the discussion of
Continue reading
STIKO Recommendations for Covid-19 Vaccination
Covid-19 vaccination, the pandemic, discussions about various vaccines – all these topics seem to be miles away already. However, with the onset of the autumn season, the question will arise as to how one should
Continue reading Booster Vaccination (3rd Vaccination against SARS-CoV2)
I would have very much wished not to have to write about this complex of topics anymore – but the current situation makes the topic of vaccination against COVID19 very topical again – and the
Continue reading
ECTRIMS 2021 (2): Vaccination in Multiple Sclerosis – Joint Consensus from ECTRIMS and EAN
The pandemic and the discussions about vaccinating MS patients against COVID19 have shown the need for a common European approach regarding recommendations for vaccinating MS sufferers. Therefore, after the last ECTRIMS Congress in 2020, representatives
Continue reading
ECTRIMS 2021 (4): When to stop therapy, when to extend the interval?
How long should immunotherapy for MS be continued? When can therapy be stopped? These are questions that not only concern MS patients but also many neurologists. Of course, one can take the position that long-lasting
Continue reading ECTRIMS 2021 (1): Vaccination against SARS-CoV2
This year, the ECTRIMS Congress was again held virtually due to the pandemic. While this was a pity, as large international congresses thrive on the personal exchange between doctors and scientists, there was still plenty
Continue reading COVID 19 Vaccination and Immunotherapy – Focus on Ocrelizumab
How does immunotherapy for MS and the COVID-19 vaccination relate? This question is currently being asked frequently by my patients. As already mentioned in some blog posts about vaccination and MS, the COVID-19 vaccination poses
Continue readingPharmacovigilance Data on Ocrelizumab
In view of a number of inquiries, I assume that a work recently published in the journal Multiple Sclerosis and Related Disorders (MSARD) has caused some confusion. The work deals with the occurrence of COVID-19
Continue reading
That was 2019 …
The year is coming to an end. Also in 2019, there were many interesting news for MS patients, which I also partly commented on in this blog. In my opinion, nothing really groundbreaking has happened.
Continue reading
